Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5940 Target Snapshot

Serine/threonine-protein kinase MARK1 · SINGLE PROTEIN · Homo sapiens

1,086Compounds
322Assays
5Approved Drugs
163.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt Q9P0L2. Use UniProt Q9P0L2 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q9P0L2 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Serine/threonine-protein kinase MARK1 as ChEMBL target CHEMBL5940, mapped to UniProt Q9P0L2. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Serine/threonine-protein kinase MARK1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL5940
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q9P0L2
Serine/threonine-protein kinase MARK1
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Serine/threonine-protein kinase MARK1 is the right protein anchor across sources, using UniProt Q9P0L2 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSerine/threonine-protein kinase MARK1
UniProt AccessionQ9P0L2
Component TypeProtein
Sequence Length795 aa

Serine/threonine-protein kinase MARK1

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Serine/threonine-protein kinase MARK1, mapped to UniProt Q9P0L2. Sequence length is 795 aa.

Mapped IDQ9P0L2
Review nameSerine/threonine-protein kinase MARK1
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

5
Approved
3
Phase III
5
Phase II
1
Phase I
Assay Mix

Activity Type Distribution

IC5036.0
KI4.0
KD123.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL388978 9.58 IC50 0.261 Preclinical
CHEMBL5305160 8.7 IC50 2.0 Preclinical
CHEMBL4576489 8.52 Kd 3.0 Preclinical
CHEMBL388978 8.4 Kd 4.0 Preclinical
CHEMBL4116008 8.4 IC50 4.0 Clinical
CHEMBL4465866 8.05 Kd 9.0 Preclinical
CHEMBL3605057 7.57 IC50 27.0 Preclinical
CHEMBL509032 7.51 Kd 31.0 Preclinical
CHEMBL603469 7.08 Kd 83.0 Clinical
CHEMBL1940251 6.96 IC50 110.0 Preclinical
Distribution

pChEMBL Value Distribution

5
5.0
10
5.5
7
6.0
9
6.5
2
7.0
2
7.5
4
8.0
2
8.5
2
9.0
1
9.5
pChEMBL
Approved Drugs

Approved Drugs

FEDRATINIB
CHEMBL1287853
Approved 2019
BRIGATINIB
CHEMBL3545311
Approved 2017
MIDOSTAURIN
CHEMBL608533
Approved 2017
Assay Landscape

Assay Landscape

322
Total Assays
35
Tested Compounds
1
Assay Types
Binding — 322 assays, 35 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 246 33 6.5
assay format 45 0
cell-based format 22 2 8.3
subcellular format 9 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine